Outcome of Children with Standard‐Risk T‐Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies

Children with T‐lineage acute lymphoblastic leukemia ALL (T‐ALL) historically have had inferior outcomes compared with the children with precursor‐B ALL (B‐ALL). After 1995, the Children's Cancer Group (CCG) treated patients with B‐ and T‐ALL according to the National Cancer Institute (NCI) risk criteria, basing risk stratification on age and white blood cell (WBC) count regardless of immunophenotype. The Pediatric Oncology Group (POG) treated all the patients with T‐ALL on separate, generally more intensive protocols than those used to treat the patients with B‐ALL.

[1]  V. L. Schermer,et al.  Book Review: Ruptures in the American Psyche: Containing Destructive Populism in Perilous Times , 2022, Group Analysis.

[2]  M. Loh,et al.  Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331 , 2014 .

[3]  M. Loh,et al.  T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .

[4]  J. V. van Dongen,et al.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. , 2011, Blood.

[5]  S. Lipshultz,et al.  Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). , 2011, Blood.

[6]  J. Gastier-Foster,et al.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[7]  A. Bleyer,et al.  Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. , 2010, Blood.

[8]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[9]  H. Sather,et al.  Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report , 2009, Leukemia.

[10]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[11]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[12]  N. Heerema,et al.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: Results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group , 2006 .

[13]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[14]  R. Gelber,et al.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[16]  V. Poggi,et al.  Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. , 2002, Blood.

[17]  W. Hop,et al.  Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. , 2002, Blood.

[18]  N. Heerema,et al.  Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2002, Blood.

[19]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[20]  M. Amylon,et al.  Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.

[21]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[22]  M. Schrappe,et al.  Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Sather,et al.  Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.

[24]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[25]  R. Gelber,et al.  Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Reaman,et al.  Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Sather,et al.  Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Behm,et al.  Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.

[29]  H. Sather,et al.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Shuster,et al.  Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. , 1988, Blood.

[31]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[32]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Borowitz,et al.  Clinicopathologic aspects of E rosette negative T cell acute lymphocytic leukemia: a Pediatric Oncology Group study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Cooper,et al.  Pediatric Oncology Group Utilization of Immunologic Markers in the Designation of Acute Lymphocytic Leukemia Subgroups: Influence on Treatment Response a , 1984, Annals of the New York Academy of Sciences.

[35]  M. Cooper,et al.  Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood. , 1981, Cancer research.

[36]  J. Peto,et al.  Immunologically Defined Subclasses of Acute Lymphoblastic Leukaemia in Children: their Relationship to Presentation Features and Prognosis , 1981, British journal of haematology.

[37]  R. Gelber,et al.  Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. , 1980, Blood.

[38]  R. Hurwitz,et al.  Childhood leukemia-lymphoma. Heterogeneity of phenotypes and prognoses. , 1979, American journal of clinical pathology.

[39]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[40]  W. Hop,et al.  Detection of minimal residual disease identifies differences in treatment response between TALL and precursor BALL , 2002 .

[41]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Frankel,et al.  Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. , 1992, Leukemia.

[43]  J. Shuster,et al.  Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1990, Blood.